Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation, has reported a series of significant stock transactions in a recent SEC filing. This activity, which includes both the acquisition and sale of shares, underscores Rothblatt's continuing commitment to the company and its strategic direction.

The filing, dated November 17, 2026, details transactions that occurred on November 16, 2026. Rothblatt exercised stock options to acquire 9,500 shares at a price of $117.76 each, while also selling a total of 4,000 shares at prices ranging from approximately $580 to $595. These transactions reflect a calculated approach to managing her equity stake in the company.

Background

United Therapeutics Corporation, a prominent player in the pharmaceutical preparations sector, focuses on developing innovative therapies for chronic and life-threatening conditions. The company, incorporated in Delaware, operates out of Silver Spring, Maryland. It is publicly traded under the ticker symbol UTHR.

According to its recent filings, United Therapeutics has been active in the market, with multiple transactions reported by Rothblatt over the past few weeks. This includes a series of Form 4 filings, which disclose insider transactions and ownership changes.

What the Filing Says

The SEC filing reveals that Rothblatt's recent transactions included:

  • Acquisition of 9,500 shares through the exercise of stock options.
  • Sale of 4,000 shares, with specific sales of 110 shares at $580.25, 170 shares at $581.25, and 2,108 shares at $586.72, among others.

Rothblatt’s actions were executed under a pre-arranged 10b5-1 trading plan, which allows company insiders to set up a schedule for selling stocks to avoid accusations of insider trading.

Impact

These transactions may affect various stakeholders, including investors and analysts who closely monitor executive actions for insights into company performance and strategy. Rothblatt's significant shareholdings and her active management of them signal confidence in United Therapeutics' future prospects.

What's Next

The filing does not specify what actions may follow these transactions, but continued monitoring of Rothblatt's trading activity and United Therapeutics' performance will be crucial for stakeholders.

For further details, the full filing can be accessed through the SEC's website under accession number 0001106578-26-000190.